Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(1):9–13. doi: 10.1054/bjoc.2001.1861

Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group

H Ueoka 1, M Tanimoto 1, K Kiura 1, M Tabata 1, N Takigawa 1, Y Segawa 2, I Takata 2, K Eguchi 2, N Okimoto 3, S Harita 4, H Kamei 5, T Shibayama 6, Y Watanabe 7, S Hiraki 7, M Harada 1
PMCID: PMC2363923  PMID: 11437395

Abstract

A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg m–2was given first and followed by CPT-11 at a dose of 50 mg m–2. Both drugs were given by 1-hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles. 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32–63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: phase II study, irinotecan, cisplatin, fractionated administration, non-small-cell lung cancer

Full Text

The Full Text of this article is available as a PDF (61.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000 Dec 15;60(24):6921–6926. [PubMed] [Google Scholar]
  2. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Jiroutek M., Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623–631. doi: 10.1200/JCO.2000.18.3.623. [DOI] [PubMed] [Google Scholar]
  3. Bunn P. A., Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May;4(5):1087–1100. [PubMed] [Google Scholar]
  4. DeVore R. F., Johnson D. H., Crawford J., Garst J., Dimery I. W., Eckardt J., Eckhardt S. G., Elfring G. L., Schaaf L. J., Hanover C. K. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2710–2720. doi: 10.1200/JCO.1999.17.9.2710. [DOI] [PubMed] [Google Scholar]
  5. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16–20. doi: 10.1200/JCO.1992.10.1.16. [DOI] [PubMed] [Google Scholar]
  6. Grilli R., Oxman A. D., Julian J. A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993 Oct;11(10):1866–1872. doi: 10.1200/JCO.1993.11.10.1866. [DOI] [PubMed] [Google Scholar]
  7. Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988 Apr 1;48(7):1722–1726. [PubMed] [Google Scholar]
  8. Johnson D. H. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience. Chest. 2000 Apr;117(4 Suppl 1):133S–137S. doi: 10.1378/chest.117.4_suppl_1.133s. [DOI] [PubMed] [Google Scholar]
  9. Kobayashi K., Shinbara A., Kamimura M., Takeda Y., Kudo K., Kabe J., Hibino S., Hino M., Shibuya M., Kudoh S. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother Pharmacol. 1998;42(1):53–58. doi: 10.1007/s002800050784. [DOI] [PubMed] [Google Scholar]
  10. Kudoh S., Takada M., Masuda N., Nakagawa K., Itoh K., Kusunoki Y., Negoro S., Matsui K., Takifuji N., Morino H. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res. 1993 Feb;84(2):203–207. doi: 10.1111/j.1349-7006.1993.tb02856.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987 Nov 15;47(22):5944–5947. [PubMed] [Google Scholar]
  12. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  13. Masuda N., Fukuoka M., Fujita A., Kurita Y., Tsuchiya S., Nagao K., Negoro S., Nishikawa H., Katakami N., Nakagawa K. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer. 1998 Jul;78(2):251–256. doi: 10.1038/bjc.1998.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Masuda N., Fukuoka M., Kudoh S., Kusunoki Y., Matsui K., Nakagawa K., Hirashima T., Tamanoi M., Nitta T., Yana T. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol. 1994 Jan;12(1):90–96. doi: 10.1200/JCO.1994.12.1.90. [DOI] [PubMed] [Google Scholar]
  15. Masuda N., Fukuoka M., Takada M., Kusunoki Y., Negoro S., Matsui K., Kudoh S., Takifuji N., Nakagawa K., Kishimoto S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol. 1992 Nov;10(11):1775–1780. doi: 10.1200/JCO.1992.10.11.1775. [DOI] [PubMed] [Google Scholar]
  16. Negoro S., Fukuoka M., Masuda N., Takada M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Niitani H., Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991 Aug 21;83(16):1164–1168. doi: 10.1093/jnci/83.16.1164. [DOI] [PubMed] [Google Scholar]
  17. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  18. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]
  19. Ueoka H., Tabata M., Kiura K., Shibayama T., Gemba K., Segawa Y., Chikamori K., Yonei T., Hiraki S., Harada M. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer. 1999 Feb;79(5-6):984–990. doi: 10.1038/sj.bjc.6690157. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES